Sage and Biogen unable to convince markets on zuranolone

16 February 2022
sage-large

US biotech companies Sage Therapeutics (Nasdaq: SAGE) and Biogen (Nasdaq: BIIB) have announced that the CORAL study in people with major depressive disorder (MDD) met the trial objectives.

This was achieved by the drug’s use alongside an open-label standard of care antidepressant (ADT) demonstrating a rapid and statistically-significant reduction in depressive symptoms at day three and over the two-week treatment period, achieving the primary and key secondary endpoints.

The companies focused on the positives from the trial findings, ignoring questions over the long-term effect of zuranolone, which has been doubted by investors in the past.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology